An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase

The hemitartrate salt of a compound represented by the following structural formula: (Formula I Hemitartrate), which may be used in pharmaceutical applications, are disclosed. Particular single crystalline forms of the Formula (I) Hemitartrate are characterized by a variety of properties and physica...

Full description

Saved in:
Bibliographic Details
Main Authors LIU, HANLAN, WILLIS, CHRIS, BHARDWAJ, RENU, MARSHALL, JOHN, COPELAND, DIANE P, PALACE, GERARD, SKELL, JEFFREY, KOCHLING, JIANMEI, SIEGEL, CRAIG, PETERSCHMITT, JUDITH, HARIANAWALA, ABIZER, CHENG, SENG
Format Patent
LanguageEnglish
Published 12.05.2016
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The hemitartrate salt of a compound represented by the following structural formula: (Formula I Hemitartrate), which may be used in pharmaceutical applications, are disclosed. Particular single crystalline forms of the Formula (I) Hemitartrate are characterized by a variety of properties and physical measurements. As well, methods of producing crystalline Formula (I) Hemitartrate, and using it to inhibit glucosylceramide synthase or lowering glycosphingolipid concentrations in subjects to treat a number of diseases, are also discussed. Pharmaceutical compositions are also described.
Bibliography:Application Number: AU20100324810